Pharmacotherapy for Pain in a Family With Inherited Erythromelalgia Guided by Genomic Analysis and Functional Profiling | Zendy

Paul Geha | Zendy; Yang Yang | Zendy; Mark Estación | Zendy; Betsy R. Schulman | Zendy; Hajime Tokuno | Zendy; A. Vania Apkarian | Zendy; Sulayman D. DibHajj | Zendy; Stephen G. Waxman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacotherapy for Pain in a Family With Inherited Erythromelalgia Guided by Genomic Analysis and Functional Profiling

Author(s) -

Paul Geha,

Yang Yang,

Mark Estación,

Betsy R. Schulman,

Hajime Tokuno,

A. Vania Apkarian,

Sulayman D. DibHajj,

Stephen G. Waxman

Publication year - 2016

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2016.0389

Subject(s) - carbamazepine , neuropathic pain , erythromelalgia , medicine , functional magnetic resonance imaging , chronic pain , placebo , sodium channel blocker , dorsal root ganglion , anesthesia , epilepsy , neuroscience , sodium channel , psychology , physical therapy , pathology , chemistry , dorsum , psychiatry , anatomy , sodium , alternative medicine , organic chemistry

There is a need for more effective pharmacotherapy for chronic pain, including pain in inherited erythromelalgia (IEM) in which gain-of-function mutations of sodium channel NaV1.7 make dorsal root ganglion (DRG) neurons hyperexcitable.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research